Outcomes analysis of an alternative formulation of PEGylated liposomal doxorubicin in recurrent epithelial ovarian carcinoma during the drug shortage era

OncoTargets and Therapy

Volumn 7, Issue , 2014, Pages 1409-1413

  Berger, Jessica L ^a   Smith, Ashlee ^a   Zorn, Kristin K ^a   Sukumvanich, Paniti ^a   Olawaiye, Alexander B ^a   Kelley, Joseph ^a   Krivak, Thomas C ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Drug shortage; Liposomal doxorubicin; Recurrent ovarian carcinoma

Indexed keywords

BEVACIZUMAB; CA 125 ANTIGEN; CARBOPLATIN; DOXORUBICIN; GEMCITABINE; LIPO DOX; UNCLASSIFIED DRUG;

ADOLESCENT; AGED; ALLERGIC REACTION; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; DISEASE COURSE; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; LEUKOPENIA; MORTALITY; MULTIPLE CYCLE TREATMENT; OVARY CARCINOMA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RECURRENT EPITHELIAL OVARIAN CARCINOMA; RETROSPECTIVE STUDY; SURVIVAL TIME; TREATMENT RESPONSE;

EID: 84907346318     PISSN: None     EISSN: 11786930     Source Type: Journal    
DOI: 10.2147/OTT.S62881     Document Type: Article

References (17)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer Clin. 2013;63(1):11-30.
2. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: a randomized phase III study of PEGylated liposomal doxorubicin versus topotecan. J Clin Oncol. 2001;19(14):3312-3322.
3. ten Bokkel Huinink W, Gore M, Carmichael J, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol. 1997;15(6):2183-2193.
4. O'Byrne KJ, Bliss P, Graham JD, et al. A Phase III study of Doxil/Caylex versus paclitaxel in platinum treated taxane naive relapsed ovarian cancer. Proc Am Soc Clin Oncol. 2002;21(Suppl; abstract 808):203a.
5. Mutch DG, Orlando M, Goss T, et al. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2007;25(19): 2811-2818.
6. Muggia FM, Hainsworth JD, Jeffers S, et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol. 1997;15(3): 987-993.
7. Gore M, Oza A, Rustin G, et al. A randomised trial of oral versus intravenous topotecan in patients with relapsed epithelial ovarian cancer. Eur J Cancer. 2002;38(1):57-63.
8. Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled Phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012;30(17):2039-2045.
9. Wagner U, Marth C, Largillier R, et al. Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients. Br J Cancer. 2012;107(4):588-591.
10. Markman M, Rothman R, Hakes T, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol. 1991;9(3):389-393.
11. Monk BJ, Herzog TJ, Kaye SB, et al. Trabectedin plus PEGylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysis. Eur J Cancer. 2012;48(15):2361-2368.
12. Rubin SC, editor. Chemotherapy of Gynecologic Cancers. 2nd ed. Philadelphia, PA, USA: Lippincott Williams & Wilkins; 2004.
13. Immordino ML, Dosio F, Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine. 2006;1(3):297-315.
14. Chou HH, Wang KL, Chen CA, et al. Pegylated liposomal doxorubicin (Lipo-Dox) for platinum-resistant or refractory epithelial ovarian carcinoma: a Taiwanese gynecologic oncology group study with long-term follow-up. Gynecol Oncol. 2006;101(3):423-428.
15. Fukuda T, Sumi T, Teramae M, et al. PEGylated liposomal for platinum-resistant or refractory Mullerian carcinoma (epithelial ovarian carcinoma, primary carcinoma of Fallopian tube and peritoneal carcinoma): a single-institutional experience. Oncol Lett. 2013;5(1): 35-38.
16. Gorumlu G, Kucukzeybek Y, Kemal-Gul M. Pegylated liposomal doxorubicin in heavily pretreated epithelial ovarian cancer patients. J BUON. 2008;13(3):349-352.
17. Chabner BA. Drug shortages-a critical challenge for the generic drug market. N Engl J Med. 2011;365(12):2147-2149.